'Genotype 1' presentation slideshows

DHS/PP

2005 Asilomar HIV/AIDS Medical Update David H. Spach, MD Clinical Director, Northwest AIDS Education and Training Center Professor of Medicine, Division of Infectious Diseases University of Washington, Seattle. DHS/PP. HIV/AIDS: 2005 Antiretroviral Therapy Update.

864 views • 67 slides

Objectives

719 views • 60 slides

Novel Protease Inhibitors for Hepatitis C

Novel Protease Inhibitors for Hepatitis C. Brittany Holt Kelly Kerr 4/30/09. Project Goals. Determine manufacturing and commercialization efforts, including the FDA approval process for a new orally available hepatitis C NS3/NS4A protease inhibitor (SCH 503034, Boceprevir)

761 views • 54 slides

Novel Protease Inhibitors for Hepatitis C

Novel Protease Inhibitors for Hepatitis C. Brittany Holt Kelly Kerr 4/30/09. Project Goals. Determine manufacturing and commercialization efforts, including the FDA approval process for a new orally available hepatitis C NS3/NS4A protease inhibitor (SCH 503034, Boceprevir)

695 views • 54 slides

HCV update

HCV update. Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014 amoe@mednet.ucla.edu. Goals:. 1) terminology of hep C 2) benefits of hep C treatment 3 )drug interaction issues with HIV meds

726 views • 53 slides

Genetic analysis of human disorders

622 views • 46 slides

Treatment of Chronic Hepatitis C in HCV-HIV Infected Patients

651 views • 39 slides

Individualisation of HCV Therapy

Individualisation of HCV Therapy. Achieving an SVR What is the evidence? Dr Allister J Grant. Achieving an SVR. The ability to achieve SVR is the result of two independent steps: 1. Achieving a virologic response a. Interferon/peginterferon dose b. The presence of ribavirin

515 views • 37 slides

Hepatitis C Drug Pipeline

Hepatitis C Drug Pipeline. HCV WORLD CAB ? FEBRUARY 2014 BANGKOK, THAILAND. When to Treat HCV. HCV Direct-Acting Antivirals ( DAAs ) in development. Know your epidemic: what matters HCV treatment overview : now & in the near future Strategies for scaling up.

547 views • 31 slides

New Treatment for Hep C

New Treatment for Hep C. Prabhdeep Sidhu Candidate PharmD 2015 Western University of Health Sciences Mar 28, 2014. Objectives. Discuss epidemiology of Hepatitis C Explain testing and diagnosis Describe current treatments Explain new medication Sovaldi Identify place in treatment

361 views • 23 slides

The next generation of Treatment for Hepatitis C

The next generation of Treatment for Hepatitis C. Treatment of CHC: Outcomes. Goal of therapy is to render the patient PCR negative for HCV RNA Need to remain PCR negative 6 months after end of therapy Response rates for combination therapy Genotype 1 up to 40% Genotypes 2 or 3 up to 80%.

303 views • 22 slides

Harvoni Medication For Hepatitis C | Velpatasvir And Sofosbuvir | Hepatitis C | Chawla Medicos

Combination of ledipasvir and -sofosbuvir, hervoni tablets are used to treat chronic and long lasting hepatitis C and other liver infections. Contact Us: 91-9999098733 http://www.chawlamedicos.com/product/harvoni-tablets/

292 views • 22 slides

NI Hepatitis B and C Network: Diagnosis and Treatment

NI Hepatitis B and C Network: Diagnosis and Treatment. Developments in 2011/12 Introduction of new treatments for hepatitis C Near patient testing for ethnic groups Treatment of HBV in pregnancy Closing the gap.

285 views • 14 slides

Experience in Testing of Genotypes of B19

Experience in Testing of Genotypes of B19. B19 Virus Testing. NAT Testing Operations. Testing of plasma donation samples QC testing of plasma fractionation pools Example Talecris B19 virus testing system: Donation mini pool test - Qualitative NAT assay*

239 views • 13 slides

Hepatitis C

Hepatitis C. What Is Hep C? Hepatitis C (HCV) is one of several viruses that causes hepatitis (inflammation of the liver). HCV is spread most efficiently through exposure to infected blood. The presence of HCV in the liver triggers the human immune system, which leads to inflammation.

474 views • 11 slides

Hepititis C

Hepititis C. What Is Hep C?. Causes, incidence, and risk factors Hepatitis C infection is caused by the hepatitis C virus (HCV). People who may be at risk for hepatitis C are those who: Have been on long-term kidney dialysis

224 views • 11 slides

QUEST-2 Study : SMV + PEG-IFN + RBV for genotype 1

255 views • 8 slides

Detection of Parvovirus B19 Variants in Factor VIII Concentrates

Detection of Parvovirus B19 Variants in Factor VIII Concentrates. Mei-ying W. Yu 1 , Yansheng Geng 1 , Susan Wong 2 , Kevin Brown 3 ; 1 CBER/FDA, U.S.A.; 2 NHLBI/NIH, U.S.A.; 3 HPA, UK SoGAT XIX Bern, Switzerland 15 June 2006. Procedures for Detecting Genotypes 2 and 3.

234 views • 8 slides

IMPACT S tudy : SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease

64 views • 6 slides

Treatment regimens

56 views • 5 slides